Blood Biomarkers Assessed In Amyotrophic Lateral Sclerosis Prognosis
By LabMedica International staff writers Posted on 06 Aug 2014 |
Image: Histology of amyotrophic lateral sclerosis showing markedly degenerated anterior spinal nerve root (cross section) with extensive demyelination (Photo courtesy of Dr. Hidehiro Takei, MD).
Various biological markers have been proposed as potentially related to a better amyotrophic lateral sclerosis (ALS) outcome including dyslipidemia, elevated levels of uric acid, and creatinine, and reduced granulocyte count.
The blood biomarkers serum albumin and creatinine appear to be associated with survival in patients with ALS and may help define prognosis in patients after they are diagnosed with the fatal neurodegenerative disorder commonly known as Lou Gehrig disease.
Neuroscientists from the University of Turin (Italy) examined blood markers at ALS diagnosis in population-based group of 712 patients, the discovery cohort in Italy, and then replicated the findings in another group of 122 patients, the validation cohort, from an ALS tertiary center. The following biomarkers were investigated and correlated with survival: total leukocytes, neutrophils, lymphocytes, monocytes, glucose, creatinine, uric acid, albumin, bilirubin, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, creatine kinase, thyroid-stimulating hormones, and erythrocyte sedimentation rate.
The team reported significant differences in patients whose serum albumin was less than or equal to 4.3 mg/dL; creatinine levels in men of less than or equal 0.82 mg/dL, while in women creatinine levels less than or equal 0.65 mg/dL; and lymphocyte count in both sexes of less than or equal to 1,700/μL. These results were significantly associated with ALS outcome in both sexes with a dose-response effect with better survival with increasing levels. These findings were confirmed in the validation cohort. In patients with ALS, serum albumin was correlated with markers of inflammatory state while serum creatinine was correlated with fat-free mass, which is a marker of muscle mass.
The authors concluded that both creatinine and albumin are reliable and easily detectable blood markers of the severity of motor dysfunction in ALS and could be used in defining patients' prognosis at the time of diagnosis. Longitudinal studies on the variations in serum albumin and creatinine levels and their relationships to clinical status will help determine whether and how these clinical chemical factors vary during the progression of the disease. The study was published on July 21, 2014, in the journal JAMA Neurology.
Related Links:
University of Turin
The blood biomarkers serum albumin and creatinine appear to be associated with survival in patients with ALS and may help define prognosis in patients after they are diagnosed with the fatal neurodegenerative disorder commonly known as Lou Gehrig disease.
Neuroscientists from the University of Turin (Italy) examined blood markers at ALS diagnosis in population-based group of 712 patients, the discovery cohort in Italy, and then replicated the findings in another group of 122 patients, the validation cohort, from an ALS tertiary center. The following biomarkers were investigated and correlated with survival: total leukocytes, neutrophils, lymphocytes, monocytes, glucose, creatinine, uric acid, albumin, bilirubin, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, creatine kinase, thyroid-stimulating hormones, and erythrocyte sedimentation rate.
The team reported significant differences in patients whose serum albumin was less than or equal to 4.3 mg/dL; creatinine levels in men of less than or equal 0.82 mg/dL, while in women creatinine levels less than or equal 0.65 mg/dL; and lymphocyte count in both sexes of less than or equal to 1,700/μL. These results were significantly associated with ALS outcome in both sexes with a dose-response effect with better survival with increasing levels. These findings were confirmed in the validation cohort. In patients with ALS, serum albumin was correlated with markers of inflammatory state while serum creatinine was correlated with fat-free mass, which is a marker of muscle mass.
The authors concluded that both creatinine and albumin are reliable and easily detectable blood markers of the severity of motor dysfunction in ALS and could be used in defining patients' prognosis at the time of diagnosis. Longitudinal studies on the variations in serum albumin and creatinine levels and their relationships to clinical status will help determine whether and how these clinical chemical factors vary during the progression of the disease. The study was published on July 21, 2014, in the journal JAMA Neurology.
Related Links:
University of Turin
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines